New insights into SARS-CoV-2 immunity gained from natural infection

NewsGuard 100/100 Score

Antibody-secreting cells (ASCs) peaked at 3-4 weeks and were still being produced at 3-4 months in patients hospitalized with COVID-19, according to a study published in the peer-reviewed journal Viral Immunology.

Diane Griffin, MD, PhD, from Johns Hopkins Bloomberg School of Public Health, and coauthors, analyzed the blood of 55 patients hospitalized up to four months after onset of COVID-19 symptoms. They reported spike (S)- and nucleocapsid (N)-specific IgM and IgG ASCs within two weeks.

The investigators found that: "Patients with more severe disease produced more S-specific IgM and IgG ASCs than those with mild disease and had higher levels of both N- and S-specific antibody in plasma." The findings predict a more durable immune response in patients recovering from more severe disease.

This is a highly relevant and timely article because it provides scientific insights into the contribution of SARS-CoV-2 immunity gained from natural infection. The level of immunity potentially generated from actual infection with the virus has been a topic of intense debate since the beginning of the pandemic."

Rodney S. Russell, PhD, Editor-in-Chief of Viral Immunology, Memorial University of Newfoundland, St. John's

Journal reference:

Bartlett, M.L., et al. (2022) Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19. Viral Immunology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows potential for universal flu vaccine with broad antibody response